RT Journal Article
SR Electronic
T1 Multimodal Thrombectomy Device for Treatment of Acute Deep Venous Thrombosis
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.02.21.481340
DO 10.1101/2022.02.21.481340
A1 Usama Ismail
A1 Roger A. Rowe
A1 John Cashin
A1 Guy M. Genin
A1 Mohamed Zayed
YR 2022
UL http://biorxiv.org/content/early/2022/02/22/2022.02.21.481340.abstract
AB Deep vein thrombosis (DVT) is a potentially deadly medical condition that is costly to treat and impacts thousands of Americans every year. DVT is characterized by the formation of blood clots within the deep venous system of the body. If a DVT dislodges it can lead to venous thromboembolism (VTE) and pulmonary embolism (PE), both of which can lead to significant morbidity or death. Current treatment options for DVT are limited in both effectiveness and safety, in part because the treatment of the DVT cannot be confined to a defined sequestered treatment zone. We therefore developed and tested a thrombectomy device that enables the sequesteration of a DVT to a defined treatment zone during fragmentation and evacuation. We observed that, compared to a predicate thrombectomy device, the sequestered approach reduced distal DVT embolization during ex vivo thrombectomy. The sequestered approach also facilitated isovolumetric infusion and suction that enabled clearance of the sequestered treatment zone without significantly impacting vein wall diameter. Results suggest that our novel device using sequestered therapy holds promise for the treatment of high risk large-volume DVTs.Competing Interest StatementG.M.G. and M.A.Z. have equity in Caeli Vascular, Inc., which specializes in developing treatments for venous disease. U.I. and R.A.R are employed by Caeli Vascular, Inc..